Top Tweets for #s1pr

over 4 years ago

Mark S. Freedman, MD (@MSDoc_Freedman) reviews the role of #S1PR modulators in #MS in this new CME activity! #Neurology #MedEd https://t.co/OTcjtTHvUW

0

3

2

0

over 4 years ago

Apply the latest clinical data on #S1PR modulators into individualized #MS treatment plans in this discussion featuring expert Mark S. Freedman, MD (@MSDoc_Freedman) #MultipleSclerosis #MedEd https://t.co/OTcjtTHvUW

0

5

2

0

over 4 years ago

Assess the benefits and risks associated with #S1PR modulators in managing #MultipleSclerosis based on the most recent clinical data. Featuring Mark S. Freedman, MD (@MSDoc_Freedman) #MedEd https://t.co/OTcjtTHvUW

0

3

2

0

Joshua M. Steinberg, MD @joshsteinbergMD

over 4 years ago

Mark S. Freedman, MD (@MSDoc_Freedman) reviews the role of #S1PR modulators in #MS in this new CME activity! #Neurology #MedEd https://t.co/OTcjtTHvUW

0

3

2

0

roypounder.apt @APandT

almost 5 years ago

'The sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis: a unique therapeutic target in inflammatory bowel disease' #IBD #S1PR #treatment Read at https://t.co/RuvDaAM9D5

0

3

2

0

almost 6 years ago · Chicago

Awesome, rapid fire learning in this #MNIBDtweetorial by @IBD_Afzali on new and emerging therapies (think #JAKi and #S1PR agents) in #UC! 👇🏻💥💊@MondayNightIBD

almost 6 years ago

@MondayNightIBD @DCharabaty @abbvie @pfizer 1/ Let’s start with a quick #IBDPoll 1⃣ ⚡️What % of your pts w/ #UC fail to achieve adequate response w/ available Rx options❓

1

13

6

1

0

4

2

0

almost 6 years ago

@MondayNightIBD @DCharabaty @abbvie @pfizer @BMC_series @NEJM @APandT @AGA_Gastro @ExpertOpinion 14/ #Tweetorial RECAP: 🔑30%-50% of pts w/ mod–sev #ulcerativecolitis have suboptimal Rx response 🔑JAK inhibition & #S1PR agonism have emerged as valuable Rx strategies 🔑Several candidates are poised to provide🆕options to address current unmet needs in #UC Rx

2

11

1

0

almost 6 years ago

@MondayNightIBD @DCharabaty @abbvie @pfizer @BMC_series @NEJM @APandT @AGA_Gastro @ExpertOpinion 13/ 🔑#Etrasimod for mod-severe #UC ✅Selective #S1PR 1,4 & 5 modulator 🔺Ph2 trial: #etrasimod 2 mg improved Mayo clinical & endoscopic scores vs PBO 👇👇@AGA_Gastro 🔺 Mild AEs 🔺Ph3 trials underway

IBD_Afzali's tweet photo. @MondayNightIBD @DCharabaty @abbvie @pfizer @BMC_series @NEJM @APandT @AGA_Gastro @ExpertOpinion 13/ 🔑#Etrasimod for mod-severe #UC
✅Selective #S1PR 1,4 & 5 modulator
🔺Ph2 trial: #etrasimod 2 mg improved Mayo clinical & endoscopic scores vs PBO 👇👇@AGA_Gastro
🔺 Mild AEs
🔺Ph3 trials underway https://t.co/vrJDldX7Dg

1

6

1

0

almost 6 years ago

@MondayNightIBD @DCharabaty @abbvie @pfizer @BMC_series @NEJM @APandT @AGA_Gastro @ExpertOpinion 12/ 🔑 #ozanimod in moderate to severe #UC ✅Selective #S1PR 1&5 modulator 🔺Multicenter Ph3 #TrueNorth RCT ✅Efficacy & safety of #ozanimod in active UC w/ inadequate response to prior therapy 👇👇

IBD_Afzali's tweet photo. @MondayNightIBD @DCharabaty @abbvie @pfizer @BMC_series @NEJM @APandT @AGA_Gastro @ExpertOpinion 12/ 🔑 #ozanimod in moderate to severe #UC
✅Selective #S1PR 1&5 modulator
🔺Multicenter Ph3 #TrueNorth RCT
✅Efficacy & safety of #ozanimod in active UC w/ inadequate response to prior therapy 👇👇 https://t.co/rDduExWbS5

1

6

1

0

almost 6 years ago

@MondayNightIBD @DCharabaty @abbvie @pfizer @BMC_series @NEJM @APandT @AGA_Gastro 11/ 🔑#S1PR agonism 🔺 Novel strategy in the treatment of #UlcerativeColitis 🔺 PO meds 🔺Targets lymphocyte recirculation, through blockade of lymphocyte egress from the lymph nodes 👇👇 @ExpertOpinion

IBD_Afzali's tweet photo. @MondayNightIBD @DCharabaty @abbvie @pfizer @BMC_series @NEJM @APandT @AGA_Gastro 11/ 🔑#S1PR agonism
🔺 Novel strategy in the treatment of #UlcerativeColitis
🔺 PO meds
🔺Targets lymphocyte recirculation, through blockade of lymphocyte egress from the lymph nodes 👇👇
@ExpertOpinion https://t.co/Z3Qs1KN2FN

1

5

1

0